Topics:

Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen

Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

All patients in the trial will have the option to continue taking sunitinib or be switched from placebo to sunitinib. The full data set from this trial is being analyzed and more details will be presented at an upcoming scientific meeting.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.